1989
DOI: 10.1001/archderm.125.10.1359
|View full text |Cite
|
Sign up to set email alerts
|

Cyclosporine inhibits basic fibroblast growth factor-driven proliferation of human endothelial cells and keratinocytes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
12
0

Year Published

1992
1992
2013
2013

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 0 publications
1
12
0
Order By: Relevance
“…It has been shown that cyclosporin, a potent inhibitor of cyclophilins, could reverse chemoresistance in patients with gynecologic malignancies [29]. Whether combining cyclosporine A with cisplatinum can help to overcome PPIA induced chemoresistance in patients with malignant glioma is currently under investigation [31]. In addition, cyclosporin A plays a further potentially useful role as an inhibitor of angiogenesis [30,31], and non-immunosuppressive analogues of might be safely applied as part of an anti-angiogenetic drug regimen [32].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It has been shown that cyclosporin, a potent inhibitor of cyclophilins, could reverse chemoresistance in patients with gynecologic malignancies [29]. Whether combining cyclosporine A with cisplatinum can help to overcome PPIA induced chemoresistance in patients with malignant glioma is currently under investigation [31]. In addition, cyclosporin A plays a further potentially useful role as an inhibitor of angiogenesis [30,31], and non-immunosuppressive analogues of might be safely applied as part of an anti-angiogenetic drug regimen [32].…”
Section: Discussionmentioning
confidence: 99%
“…Whether combining cyclosporine A with cisplatinum can help to overcome PPIA induced chemoresistance in patients with malignant glioma is currently under investigation [31]. In addition, cyclosporin A plays a further potentially useful role as an inhibitor of angiogenesis [30,31], and non-immunosuppressive analogues of might be safely applied as part of an anti-angiogenetic drug regimen [32]. As in our study, PPIC positive CTCs were more likely in follow-up samples of the platinum resistant than in platinum sensitive patients, we speculate that PPIC positive CTCs represent a subpopulation of circulating tumor cells which "survived" chemotherapy and have a more aggressive potential.…”
Section: Discussionmentioning
confidence: 99%
“…The ability of CsA to inhibit endothelial cell proliferation and angiogenesis has also been known for some time, but CsA has not been used as a clinical angiogenesis inhibitor due to its immunosuppressive properties and nephrotoxic side effects at high doses [28], [29]. Interestingly, while the mechanism for immunosuppression by CsA is due to inhibition of the protein phosphatase calcineurin in T cells, the antiangiogenic properties of the drug are independent of calcineurin [30], [31].…”
Section: Discussionmentioning
confidence: 99%
“…the calcineurin‐inhibitors as ‘T lymphocyte‐specific’ and mycophenolic acid as ‘lymphocyte‐specific’. However, even those drugs can affect other cell types, such as endothelial cells and keratinocytes for the calcineurin‐inhibitors [8,9] and vascular smooth muscle cells and endothelial cells for mycophenolic acid [10,11]. The most unspecific substances in common use as immunosuppressants are the steroids, which are utilized not only for prophylaxis but also for therapeutic intervention at already established rejection.…”
Section: Discussionmentioning
confidence: 99%